Proton Pump Inhibitors Market, By Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, Others), By Disease Indication (Ulcers, Gastroesophageal Reflux Disease, Others), By Dosage Form (Tablet, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jun 2024

Code : CMI4225

Pages :175

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Proton Pump Inhibitors Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Launch of new products

Global proton pump inhibitors market is witnessing growth due to rising number of new product launches by major pharma companies. PPIs are commonly used to reduce excess stomach acid and provide relief from conditions like acid reflux, ulcers and gastroesophageal reflux disease (GERD). Many companies are focusing on developing advanced and more effective PPI formulations to expand their portfolios and market share. Some new products offer dual relief from acid reflux and heartburn symptoms with just one pill. These work faster and for longer duration as compared to existing drugs. Other new launches combine PPIs with other medicines to manage concurrent conditions like H. pylori infection, which causes ulcers. Some companies are also developing PPIs with improved tolerability and reduced interaction with other medications. For instance, in March 2021, Xiromed LLC, a generic division of Insud Pharmaceuticals, introduced Omeprazole Delayed-Release Capsules, 20mg, as a generic equivalent of Prilosec.

Key Players Insights